Overview

Anastrozole Arimidex remains a front-line option precisely because it addresses the limitation clinicians hit with older anti-estrogen pills. For buyers serving postmenopausal breast-cancer programs, knowing when this aromatase inhibitor fits after tamoxifen resistance protects formulary value. This piece focuses on the resistance angle and practical switching.

How It Works

Anastrozole binds and irreversibly inactivates the aromatase enzyme, which converts androgens into estradiol in peripheral tissue. By cutting estradiol synthesis, it removes the growth stimulus that drives hormone-receptor-positive tumor cells in postmenopausal patients. Because it acts downstream of the estrogen receptor rather than blocking the receptor directly, it offers a distinct mechanism from tamoxifen and is useful when receptor-blockade alone has failed.

Indications

Anastrozole is indicated for adjuvant treatment of hormone-receptor-positive early breast cancer in postmenopausal women, and for first-line or second-line therapy of advanced disease. It is chosen when prior tamoxifen is unsuitable or when resistance to selective estrogen-receptor modulators has emerged. It is not intended for premenopausal patients without ovarian suppression.

Dosage & Administration

The dose is one 1 mg tablet taken orally once daily, with or without food, continued for the prescribed duration. No tapering is required. Bone-density monitoring is recommended during long-term use because estrogen deprivation affects mineral turnover. Dose adjustments for hepatic impairment are generally not needed at this low daily strength.

Treatment is generally continued for the full adjuvant duration prescribed by the oncology team, and stopping early should only follow explicit clinical reassessment.

Storage & Sourcing

Tablets store at 20 to 25 °C in a dry place, away from direct light. For procurement, Anastrozole is a high-volume, long-course product, so forecast against multi-year adjuvant schedules rather than single cycles. Verify GMP status and batch documentation, and keep packaging moisture-resistant for humid-climate distribution.

Because courses run for years, rotate stock by expiry and store away from bathroom humidity to preserve tablet integrity over long periods.

FAQ

Q: What should buyers know about switching a patient from tamoxifen to Anastrozole? A: Switching is common after tamoxifen resistance or intolerance; confirm postmenopausal status and obtain prescriber direction, since the two drugs work through different pathways.

Q: Can resistance develop to Anastrozole itself? A: Yes, acquired resistance can emerge through ESR1 mutations or bypass pathways; document response and be ready to step to another class such as fulvestrant when progression appears.

Q: Does long-term use create a different sourcing burden? A: Five-year adjuvant courses mean steady, predictable demand, so negotiate stable pricing and reliable batch continuity rather than one-off purchases.